ENZYGNOST(R) TOXOPLASMOSIS/IGG— 510(k) K913731

Name: FDA 510(k) clearance K913731
Creator: U.S. Food and Drug Administration
Published: 1992-04-29

Substantially Equivalent

Behring Diagnostics, Inc.

FDA 510(k) clearance K913731 for ENZYGNOST(R) TOXOPLASMOSIS/IGG, Substantially Equivalent on 1992-04-29. Applicant: Behring Diagnostics, Inc.. Device class: 2.

Clearance details

Applicant: Behring Diagnostics, Inc.
Product code: Code LGD
Device class: Class 2
Regulation: 21 CFR 866.3780
Advisory panel: Microbiology
Date received: 1991-08-20
Decision date: 1992-04-29
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Somerville, NJ, US

Download summary PDF View on FDA.gov ↗

Recent devices under product code LGD

view all

K242022 — Access Toxo IgG2025-03-28
K242095 — Access Toxo IgM II2024-10-11
K233932 — Alinity i Toxo IgM2024-08-30
K210596 — ARCHITECT Toxo IgG2022-05-19
K162678 — Elecsys Toxo IgM, Elecsys Toxo IgM PreciControl2017-06-23

More clearances from Behring Diagnostics, Inc.

view all

K973832 — OPUS HLH CONTROLS1997-10-27
K972929 — N ANTISERUM TO HUMAN ALBUMIN1997-10-20
K972840 — N ANTISERUM TO HUMAN TRANSFERRIN1997-10-17
K973202 — MODIFICATION OF OPUS FERRITIN TEST SYSTEM1997-09-12
K972316 — OPUS D-DIMER1997-09-09

Adverse events under product code LGD

product code LGD

Malfunction: 502
Total: 502

Source: openFDA MAUDE database, 2020-01-01 through 2026-04-23. Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.